Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Jaguar Health, Inc.

< Previous 1 2 3 Next >
News headline image
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Launch of Mytesi Telehealth Program
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Provides Company Updates and Reports 2021 Financials
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
News headline image
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.